A Randomized, Single-blind, Single-dose, 3-arm, Parallel Group Study to Determine the Pharmacokinetic Similarity of ABP 710 and Infliximab (Remicade 'Registered Trademark') in Healthy Adult Subjects

Trial Profile

A Randomized, Single-blind, Single-dose, 3-arm, Parallel Group Study to Determine the Pharmacokinetic Similarity of ABP 710 and Infliximab (Remicade 'Registered Trademark') in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Inflammation; Rheumatic disorders
  • Focus Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 17 Jun 2017 Results comparing pharmacokinetics of ABP-710 and infliximab sourced from the European Union (n=98), presented at the 18th Annual Congress of the European League Against Rheumatism
    • 04 Jun 2015 Status changed from recruiting to completed as per Australian New Zealand Clinical Trials Registry record.
    • 31 Oct 2014 Status changed from not yet recruiting to recruiting, as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top